. 2023 Apr 4;28(6):e391–e396. doi: 10.1093/oncolo/oyad061

Table 2.

Association of confounding variables with VTE or ATE^*†.

Variable (at NSCLC diagnosis)	VTE	ATE
Variable (at NSCLC diagnosis)	HR (95% CI) ^†	HR (95% CI) ^†
ALK positive^§	1.87 (1.30-2.68)	1.24 (0.62-2.47)
Age (increasing)^¶	0.98 (0.97-0.99)	1.01 (0.99-1.02)
Sex (male)	0.86 (0.71-1.04)	1.14 (0.86-1.53)
Smoker^‡	0.69 (0.56-0.85)	0.88 (0.65-1.20)
Charlson comorbidity index	0.99 (0.95-1.03)	0.99 (0.93-1.05)
Khorana score	0.96 (0.83-1.10)	0.94 (0.79-1.13)

^*At any point from 6 months prior study index to 5 years post-index. Index date defined as date of NSCLC diagnosis.

^†Multivariate cox regression analysis with death as a competing risk.

^§Defined as ≥2 ALK-inhibitor prescriptions (crizotinib or alectinib).

^¶Hazard ratio for every 1-year increase.

^‡Past or current smoking.

Abbreviations: ALK, anaplastic lymphoma kinase; ATE, arterial thromboembolism; CI, confidence interval; HR, hazard ratio; NSCLC, non-small cell lung cancer; VTE, venous thromboembolism.